StockUS listing USRADXNASDAQHealthcareProfitless Growth

Radiopharm Theranostics Limited American Depositary Shares(RADX) Stock Analysis | Healthcare

USD --+0.00%
Reward54Moderate
Risk60Medium-High
75%Data
Revenue down 37% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 11.93M
Reward Ratingⓘ54 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ60 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RADX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Radiopharm Theranostics Limited American Depositary Shares?

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States.

AI Brief Pro

The brief on Radiopharm Theranostics Limited American Depositary Shares

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Radiopharm Theranostics Limited American Depositary Shares?

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 11.93M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (54)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.873
Insider Activity
12M windowNo data
No insider activity data available for this ticker.